H. Lundbeck (LUN) AGM 2025 summary

Opening remarks and agenda

• AGM opened with welcome remarks, highlighting global webcast access and simultaneous interpretation for shareholders worldwide.

• Outgoing chair reflected on 12 years of board service and introduced the 2024 board and management team.

• Agenda included board report, annual report adoption, profit appropriation, remuneration, board elections, auditor appointment, board proposals, and other business.

Strategic direction and leadership

• Focus on three strategic areas: growing psychiatry core, expanding neuro-specialty, and building a neuro-rare franchise.

• 2024 marked as a transformative year with record revenue, strategic brand growth, and pipeline advancement.

• Acquisition of Longboard Pharmaceuticals and initiation of major capital reallocation program.

• Board strengthened with new members, including Lars Green, bringing extensive financial and international experience.

• Dorothea Wenzel expected to be elected as Chair, bringing expertise in finance and business leadership.

Board and executive committee updates

• New CEO Charl van Zyl and a refreshed management team with international experience were introduced.

• Board composition now includes a balance of independent and dependent members, with a new member, Lars Green, elected.